乌司奴单抗赛道群雄逐鹿,国内市场爆款难期

第一财经
10 Dec 2024

全文2318字,阅读约需7分钟,帮我划重点划重点01强生研发的乌司奴单抗药物喜达诺上市以来销售额快速增长,2023年突破100亿美元大关。02由于强生相关的专利到期,2023年以来国内外多款乌司奴单抗生物类似药陆续上市。03国内药企中,华东医药的赛乐信已获批在国内上市,百奥泰、石药集团的同类品种也已递交国内上市申请并获受理。04专家认为,尽管国产生物类似药有望实现较快增长,但要孕育出50亿元甚至...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10